Clinical Trial

A Study of HQP1351 in Patients With GIST or Other Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is a Multi-center, Open-label Phase 1 Study to Determine the Recommend Phase 2 Dose (RP2D) and Evaluate PK/PD and preliminary Efficacy of HQP1351 in Patients With GIST or Other Solid Tumors.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2018-07-11; most recent amendment 2026-04-06.
Status change: Completed → Recruiting 2019-10-15
Status change: Recruiting → Completed 2019-09-17
Status change: Not Yet Recruiting → Recruiting 2018-08-09
Trial Details
NCT Number NCT03594422
Lead Sponsor Ascentage Pharma Group Inc.
Collaborators: HealthQuest Pharma Inc.
Conditions Gastrointestinal Stromal Tumor (GIST), Solid Tumor, Adult
Enrollment 100 participants
Start Date 2018-07-11
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-09